Advocacy at a Glance STEVEN GROSSMAN 11/15/24 Advocacy at a Glance STEVEN GROSSMAN 11/15/24 TBD: Final Action on FY 25 Funding In December or a CR Until Next Year? Read More Analysis and Commentary STEVEN GROSSMAN 11/15/24 Analysis and Commentary STEVEN GROSSMAN 11/15/24 FDA Impacted by the Larger Transition: Some More Q&A Read More Advocacy at a Glance STEVEN GROSSMAN 11/8/24 Advocacy at a Glance STEVEN GROSSMAN 11/8/24 Post-election Media Inquiries Read More Analysis and Commentary STEVEN GROSSMAN 11/8/24 Analysis and Commentary STEVEN GROSSMAN 11/8/24 Presidential Transition Has Arrived at FDA: Some Q&A Read More Advocacy at a Glance STEVEN GROSSMAN 11/1/24 Advocacy at a Glance STEVEN GROSSMAN 11/1/24 A Rough Couple of Months for FDA and Other Government Agencies Read More Analysis and Commentary STEVEN GROSSMAN 11/1/24 Analysis and Commentary STEVEN GROSSMAN 11/1/24 Presidential Transition: Coming Soon to the FDA Read More Advocacy at a Glance STEVEN GROSSMAN 10/18/24 Advocacy at a Glance STEVEN GROSSMAN 10/18/24 No Appropriations Action Expected Until After the Election Read More Analysis and Commentary STEVEN GROSSMAN 10/18/24 Analysis and Commentary STEVEN GROSSMAN 10/18/24 Steven Is Moving On to New FDA Challenges Read More Advocacy at a Glance STEVEN GROSSMAN 10/4/24 Advocacy at a Glance STEVEN GROSSMAN 10/4/24 Congress in Recess; Much to Do When They Return November 12 Read More Analysis and Commentary STEVEN GROSSMAN 10/4/24 Analysis and Commentary STEVEN GROSSMAN 10/4/24 We Got the FY 25 CR Story Right, What’s Next? Part 2 Read More Advocacy at a Glance STEVEN GROSSMAN 9/27/24 Advocacy at a Glance STEVEN GROSSMAN 9/27/24 House and Senate Approve Continuing Resolution Through December 20 Read More Analysis and Commentary STEVEN GROSSMAN 9/27/24 Analysis and Commentary STEVEN GROSSMAN 9/27/24 We Got the FY 25 CR Story Right, What’s Next? Read More Advocacy at a Glance STEVEN GROSSMAN 9/20/24 Advocacy at a Glance STEVEN GROSSMAN 9/20/24 House Rejects Continuing Resolution Through March 28 Read More Analysis and Commentary STEVEN GROSSMAN 9/20/24 Analysis and Commentary STEVEN GROSSMAN 9/20/24 Remembrance of October 1’s Past Read More Advocacy at a Glance STEVEN GROSSMAN 9/13/24 Advocacy at a Glance STEVEN GROSSMAN 9/13/24 Continuing Resolution Pulled from House Floor Schedule - May be Considered Next Week Read More Analysis and Commentary STEVEN GROSSMAN 9/13/24 Analysis and Commentary STEVEN GROSSMAN 9/13/24 The Pentagon is FDA’s Ally, Really! Read More Advocacy at a Glance STEVEN GROSSMAN 9/6/24 Advocacy at a Glance STEVEN GROSSMAN 9/6/24 Congress Returns September 9; Continuing Resolution Needed Read More Analysis and Commentary STEVEN GROSSMAN 9/6/24 Analysis and Commentary STEVEN GROSSMAN 9/6/24 Establishing Reasonable Expectations for the First FY 25 CR Read More Advocacy at a Glance STEVEN GROSSMAN 8/30/24 Advocacy at a Glance STEVEN GROSSMAN 8/30/24 Congress Returns September 9 But Action on Agriculture/FDA Appropriations Unlikely Read More Analysis and Commentary STEVEN GROSSMAN 8/30/24 Analysis and Commentary STEVEN GROSSMAN 8/30/24 Q&A: Bumpy September Ride for Government Funding Read More Older Posts
Advocacy at a Glance STEVEN GROSSMAN 11/15/24 Advocacy at a Glance STEVEN GROSSMAN 11/15/24 TBD: Final Action on FY 25 Funding In December or a CR Until Next Year? Read More
Analysis and Commentary STEVEN GROSSMAN 11/15/24 Analysis and Commentary STEVEN GROSSMAN 11/15/24 FDA Impacted by the Larger Transition: Some More Q&A Read More
Advocacy at a Glance STEVEN GROSSMAN 11/8/24 Advocacy at a Glance STEVEN GROSSMAN 11/8/24 Post-election Media Inquiries Read More
Analysis and Commentary STEVEN GROSSMAN 11/8/24 Analysis and Commentary STEVEN GROSSMAN 11/8/24 Presidential Transition Has Arrived at FDA: Some Q&A Read More
Advocacy at a Glance STEVEN GROSSMAN 11/1/24 Advocacy at a Glance STEVEN GROSSMAN 11/1/24 A Rough Couple of Months for FDA and Other Government Agencies Read More
Analysis and Commentary STEVEN GROSSMAN 11/1/24 Analysis and Commentary STEVEN GROSSMAN 11/1/24 Presidential Transition: Coming Soon to the FDA Read More
Advocacy at a Glance STEVEN GROSSMAN 10/18/24 Advocacy at a Glance STEVEN GROSSMAN 10/18/24 No Appropriations Action Expected Until After the Election Read More
Analysis and Commentary STEVEN GROSSMAN 10/18/24 Analysis and Commentary STEVEN GROSSMAN 10/18/24 Steven Is Moving On to New FDA Challenges Read More
Advocacy at a Glance STEVEN GROSSMAN 10/4/24 Advocacy at a Glance STEVEN GROSSMAN 10/4/24 Congress in Recess; Much to Do When They Return November 12 Read More
Analysis and Commentary STEVEN GROSSMAN 10/4/24 Analysis and Commentary STEVEN GROSSMAN 10/4/24 We Got the FY 25 CR Story Right, What’s Next? Part 2 Read More
Advocacy at a Glance STEVEN GROSSMAN 9/27/24 Advocacy at a Glance STEVEN GROSSMAN 9/27/24 House and Senate Approve Continuing Resolution Through December 20 Read More
Analysis and Commentary STEVEN GROSSMAN 9/27/24 Analysis and Commentary STEVEN GROSSMAN 9/27/24 We Got the FY 25 CR Story Right, What’s Next? Read More
Advocacy at a Glance STEVEN GROSSMAN 9/20/24 Advocacy at a Glance STEVEN GROSSMAN 9/20/24 House Rejects Continuing Resolution Through March 28 Read More
Analysis and Commentary STEVEN GROSSMAN 9/20/24 Analysis and Commentary STEVEN GROSSMAN 9/20/24 Remembrance of October 1’s Past Read More
Advocacy at a Glance STEVEN GROSSMAN 9/13/24 Advocacy at a Glance STEVEN GROSSMAN 9/13/24 Continuing Resolution Pulled from House Floor Schedule - May be Considered Next Week Read More
Analysis and Commentary STEVEN GROSSMAN 9/13/24 Analysis and Commentary STEVEN GROSSMAN 9/13/24 The Pentagon is FDA’s Ally, Really! Read More
Advocacy at a Glance STEVEN GROSSMAN 9/6/24 Advocacy at a Glance STEVEN GROSSMAN 9/6/24 Congress Returns September 9; Continuing Resolution Needed Read More
Analysis and Commentary STEVEN GROSSMAN 9/6/24 Analysis and Commentary STEVEN GROSSMAN 9/6/24 Establishing Reasonable Expectations for the First FY 25 CR Read More
Advocacy at a Glance STEVEN GROSSMAN 8/30/24 Advocacy at a Glance STEVEN GROSSMAN 8/30/24 Congress Returns September 9 But Action on Agriculture/FDA Appropriations Unlikely Read More
Analysis and Commentary STEVEN GROSSMAN 8/30/24 Analysis and Commentary STEVEN GROSSMAN 8/30/24 Q&A: Bumpy September Ride for Government Funding Read More
